京东(09618.HK):京东健康已递交上市申请表格
京东(09618.HK)公布,拟通过以京东健康股份於联交所主板独立上市的方式分拆京东健康,并已就拟议分拆向香港联交所提交分拆建议,联交所亦已确认公司可进行拟议分拆。公司表示,京东健康已於上周五(25日)透过其联席保荐人向联交所提交上市申请表格,以申请京东健康股份於联交所主板上市及买卖之批准。
公司建议,拟议分拆将以京东健康股份全球发售的方式进行,包括香港公开发售及国际发售,拟议分拆完成後,公司将间接持有京东健康不少於50%的股权,京东健康将仍为公司之子公司。现时京东健康全球发售的规模和架构及公司之股权百分比的减幅尚未落实。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.